National Institutes of Health: Melanoma trials

The registry lists 220 Melanoma studies with National Institutes of Health as lead sponsor. 14 are open to participants now and 92 have results posted.

Early Phase 1 1Phase 1 66Phase 2 147Phase 3 10No phase 18(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young AdultsNot yet recruitingNCT07891286Phase 2
• Natural History Study of Early Life Exposures in Agriculture (ELEA)Enrolling by invitationNCT07328516
• Clinical Genetics Branch Eligibility Screening SurveyNot yet recruitingNCT07005297
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2
• Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling by invitationNCT05600933
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaRecruitingNCT05155033Phase 2
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 2
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingNCT02621021Phase 2
• Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesEnrolling by invitationNCT00923026
• Harvesting Cells for Experimental Cancer TreatmentsEnrolling by invitationNCT00068003
• Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaRecruitingNCT00040352
• Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruitingNCT00001823
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruitingNCT04557956Phase 1/2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results posted
• Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerTerminatedNCT03300843Phase 2Results posted
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT02965716Phase 2Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous MelanomaCompletedNCT02581930Phase 2Results posted
• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT02506153Phase 3Results posted
• Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal MelanomaCompletedNCT02363283Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveTerminatedNCT02153905Phase 1/2Results posted
• A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedNCT02129075Phase 2Results posted
• Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaTerminatedNCT02111863Phase 2Results posted
• Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02097225Phase 1Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing MelanomaTerminatedNCT02062359Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaCompletedNCT01993719Phase 2Results posted
• Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryCompletedNCT01989572Phase 3Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerCompletedNCT01967823Phase 2Results posted
• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01950390Phase 2Results posted
• Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerCompletedNCT01902173Phase 1/2Results posted
• Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by SurgeryCompletedNCT01835145Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular MelanomaTerminatedNCT01814046Phase 2Results posted
• Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01708941Phase 2Results posted
• Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibTerminatedNCT01519427Phase 2Results posted
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor CellsTerminatedNCT01495572Phase 2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaTerminatedNCT01468818Phase 2Results posted
• Cixutumumab in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01413191Phase 2Results posted
• Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic MelanomaTerminatedNCT01369888Phase 1/2Results posted
• Modified Tumor Infiltrating Lymphocytes for Metastatic MelanomaTerminatedNCT01369875Phase 2Results posted
• Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...CompletedNCT01319565Phase 2Results posted
• Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic MelanomaTerminatedNCT01307618Phase 2Results posted
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT01274338Phase 3Results posted
• MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered LymphocytesTerminatedNCT01273181Phase 1/2Results posted
• Drosophila-generated CTLTerminatedNCT01271907Phase 2Results posted
• Lapatinib in Stage IV Melanoma With ERBB4 MutationsTerminatedNCT01264081Phase 2Results posted
• Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01258855Phase 2Results posted
• Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating LymphocytesTerminatedNCT01236573Phase 1/2Results posted
• CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic CancerTerminatedNCT01218867Phase 1/2Results posted
• RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast CancerTerminatedNCT01217411Phase 1/2Results posted
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic MelanomaCompletedNCT01196416Phase 1/2Results posted
• Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IVTerminatedNCT01166126Phase 2Results posted
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal CancerTerminatedNCT01160445Phase 2Results posted
• Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01143402Phase 2Results posted
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryActive, not recruitingNCT01134614Phase 2Results posted
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTerminatedNCT01120275Phase 2Results posted
• Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...CompletedNCT01118091Phase 2Results posted
• Dinaciclib in Treating Patients With Stage III-IV MelanomaTerminatedNCT01026324Phase 1/2Results posted
• Dinaciclib in Treating Patients With Stage IV MelanomaActive, not recruitingNCT00937937Phase 2Results posted
• Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic MelanomaTerminatedNCT00924001Phase 1/2Results posted
• Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic MelanomaCompletedNCT00923195Phase 2Results posted
• MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00866177Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by SurgeryCompletedNCT00861913Phase 2Results posted
• Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of MelanomaCompletedNCT00841204Phase 2Results posted
• Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma PatientsTerminatedNCT00706992Phase 2Results posted
• Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic CancerTerminatedNCT00704938Phase 2Results posted
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerTerminatedNCT00670748Phase 2Results posted
• Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00669019Phase 2Results posted
• Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat MelanomaCompletedNCT00665470Phase 2Results posted
• Viral Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00651157Phase 2Results posted
• Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced MelanomaTerminatedNCT00612222Phase 2Results posted
• Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced MelanomaTerminatedNCT00610311Phase 2Results posted
• Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the BrainTerminatedNCT00550654Phase 2Results posted
• Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic MelanomaCompletedNCT00513604Phase 2Results posted
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered LymphocytesTerminatedNCT00509496Phase 2Results posted
• Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered LymphocytesCompletedNCT00509288Phase 2Results posted
• Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye MelanomaTerminatedNCT00482911Phase 2Results posted
• Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2Results posted
• Lovastatin in Treating Patients At High Risk of MelanomaCompletedNCT00462280Phase 2Results posted
• VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00450255Phase 2Results posted
• Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV MelanomaCompletedNCT00436605Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT00397982Phase 2Results posted
• Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00387751Phase 2Results posted
• Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the EyeCompletedNCT00329641Phase 2Results posted
• Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney CancerCompletedNCT00328861Phase 2Results posted
• Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic MelanomaCompletedNCT00314106Phase 2Results posted
• Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By SurgeryCompletedNCT00281957Phase 2Results posted
• Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk MelanomaCompletedNCT00273910Phase 2Results posted
• AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2Results posted
• Vorinostat in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00121225Phase 2Results posted
• Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00110019Phase 3Results posted
• Lenalidomide (Revlimid) to Treat Advanced Ocular MelanomaCompletedNCT00109005Phase 2Results posted
• Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00096382Phase 2Results posted
• Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced CancersCompletedNCT00074308Phase 1/2Results posted